Evolus, Inc. (0K16.L)
USD 14.58
(0.16%)
USD 14.58
(0.16%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 188.99 Million USD | 6.19% |
| 2022 | 177.98 Million USD | -30.88% |
| 2021 | 257.48 Million USD | 23.16% |
| 2020 | 209.06 Million USD | -13.05% |
| 2019 | 240.44 Million USD | 39.92% |
| 2018 | 171.84 Million USD | 12.88% |
| 2017 | 152.23 Million USD | 96.44% |
| 2016 | 77.49 Million USD | -4.68% |
| 2015 | 81.3 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 226.17 Million USD | 19.67% |
| 2024 Q2 | 233.77 Million USD | 3.36% |
| 2023 Q3 | 167.97 Million USD | -0.6% |
| 2023 Q4 | 188.99 Million USD | 12.52% |
| 2023 FY | 188.99 Million USD | 6.19% |
| 2023 Q1 | 160.23 Million USD | -9.97% |
| 2023 Q2 | 168.98 Million USD | 5.46% |
| 2022 FY | 177.98 Million USD | -30.88% |
| 2022 Q3 | 192.71 Million USD | -8.63% |
| 2022 Q4 | 177.98 Million USD | -7.65% |
| 2022 Q2 | 210.91 Million USD | -4.42% |
| 2022 Q1 | 220.66 Million USD | -14.3% |
| 2021 Q3 | 215.22 Million USD | -10.27% |
| 2021 FY | 257.48 Million USD | 23.16% |
| 2021 Q2 | 239.86 Million USD | 52.59% |
| 2021 Q1 | 157.19 Million USD | -24.81% |
| 2021 Q4 | 257.48 Million USD | 19.64% |
| 2020 FY | 209.06 Million USD | -13.05% |
| 2020 Q1 | 214.15 Million USD | -10.93% |
| 2020 Q2 | 194.54 Million USD | -9.16% |
| 2020 Q3 | 215.77 Million USD | 10.92% |
| 2020 Q4 | 209.06 Million USD | -3.11% |
| 2019 Q1 | 220.92 Million USD | 28.56% |
| 2019 FY | 240.44 Million USD | 39.92% |
| 2019 Q4 | 240.44 Million USD | 31.63% |
| 2019 Q3 | 182.66 Million USD | -9.92% |
| 2019 Q2 | 202.78 Million USD | -8.21% |
| 2018 Q3 | 183.37 Million USD | 50.39% |
| 2018 FY | 171.84 Million USD | 12.88% |
| 2018 Q2 | 121.93 Million USD | -4.29% |
| 2018 Q1 | 127.39 Million USD | -16.32% |
| 2018 Q4 | 171.84 Million USD | -6.29% |
| 2017 FY | 152.23 Million USD | 96.44% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q2 | 146.13 Million USD | 0.0% |
| 2017 Q3 | 78.95 Million USD | -45.97% |
| 2017 Q4 | 152.23 Million USD | 92.8% |
| 2016 FY | 77.49 Million USD | -4.68% |
| 2016 Q4 | 77.49 Million USD | 0.0% |
| 2015 FY | 81.3 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 77.275% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 79.832% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 75.703% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -14.195% |
| bluebird bio, Inc. | 619.16 Million USD | 69.475% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -50.184% |
| Imunon, Inc. | 21.91 Million USD | -762.293% |
| Editas Medicine, Inc. | 499.15 Million USD | 62.136% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.292% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 94.368% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 84.233% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 94.187% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 86.586% |
| Verastem, Inc. | 149.71 Million USD | -26.236% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.767% |
| Waters Corporation | 4.62 Billion USD | 95.915% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.809% |
| Biogen Inc. | 26.84 Billion USD | 99.296% |
| Nektar Therapeutics | 398.03 Million USD | 52.517% |
| Perrigo Company plc | 10.8 Billion USD | 98.251% |
| Dynavax Technologies Corporation | 997.09 Million USD | 81.045% |
| Illumina, Inc. | 10.11 Billion USD | 98.131% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -568.49% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 75.78% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 15.059% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -187.712% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 97.238% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -14.323% |
| Adicet Bio, Inc. | 207.29 Million USD | 8.827% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 4.259% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.429% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 8.162% |
| FibroGen, Inc. | 423.52 Million USD | 55.375% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 98.244% |
| OPKO Health, Inc. | 2.01 Billion USD | 90.605% |
| Homology Medicines, Inc. | 47.05 Million USD | -301.636% |
| Geron Corporation | 394.07 Million USD | 52.04% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 95.065% |
| Exelixis, Inc. | 2.94 Billion USD | 93.577% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 48.71% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -22.419% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 85.473% |
| Zoetis Inc. | 14.28 Billion USD | 98.677% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 67.87% |
| Abeona Therapeutics Inc. | 64 Million USD | -195.3% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.169% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -237.804% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 93.679% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 94.211% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 69.591% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 89.096% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 81.987% |
| Insmed Incorporated | 1.32 Billion USD | 85.788% |
| TG Therapeutics, Inc. | 329.58 Million USD | 42.656% |
| Incyte Corporation | 6.78 Billion USD | 97.213% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 89.7% |